Piper Jaffray upgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an underweight rating to a neutral rating in a research note released on Tuesday morning, TheFlyOnTheWall.com reports. They currently have $38.00 target price on the stock, up from their previous target price of $25.00. Isis Pharmaceuticals (NASDAQ:ISIS) traded up 3.17% on Tuesday, hitting $39.35. The stock […]
Isis Pharmaceuticals Upgraded to Neutral at Piper Jaffray (ISIS) is a post from: Zolmax
The post Isis Pharmaceuticals Upgraded to Neutral at Piper Jaffray (ISIS) appeared first on Zolmax.